H&R/Dragoco acquisition
This article was originally published in The Rose Sheet
Executive Summary
Haarmann & Reimer and Dragoco fragrance and flavors businesses will be merged into one German firm under holding company Isis Vermögensverwaltung after receiving regulatory clearance from the European Commission Sept. 17. Commission concluded there is "sufficient competition in the European market" for flavors, fragrances, aroma chemicals and cosmetics and combined market share will not exceed 15% for any of the ingredients concerned. Swedish equity fund group EQT Northern Europe Private Equity Funds announced it would combine H&R, acquired from Bayer, and Dragoco into one $1.25 bil. business in June (1"The Rose Sheet" July 22, 2002, p. 3)...
You may also be interested in...
H&R/Dragoco management
Combined fragrance and flavors businesses, acquired by Swedish EQT Northern Europe Equity Funds, will be headed by Horst-Otto Gerberding as CEO, firm says following close of transaction Oct. 1. Among other management team appointments, Dan Stebbins will be in charge of flavors, while Tim Schaffner will head fragrances and cosmetics. Horst Finkelmeier will oversee aroma chemicals, Heinz-Jurgen Bertram will be in charge of R&D, Jurgen Nienhaus is named head of operations, and Martin Wolf is chief financial officer. Merger received clearance from European Commission in September (1"The Rose Sheet" Sept. 23, 2002, In Brief)...
Haarmann & Reimer, Dragoco Merger To Yield $1.25 Bil. Global Business
Haarmann & Reimer and Dragoco will be combined into a $1.25 bil. (€1=$1) flavor, fragrance and cosmetic ingredient business under an acquisition plan announced by Swedish equity fund group EQT Northern Europe Private Equity Funds, the firms announced July 17
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.